Outcomes 2016 - Baylor Hamilton Heart and Vascular Hospital FY 2016 | Page 33

1
“Firsts” for Research and
Commercial Use
INTERVENTIONAL
CARDIOLOGY “FIRSTS”
IN FY16
Evolut ™ R
1st commercial use of this
valve in North Texas
SYNERGY™
1st placement in North Texas
Tendyne
1st placement in Texas,
one of 1st in U.S.
CardioMEMs ™
1st in Dallas area
Watchman ®
1st commercial placement
in North Texas
“Bringing advanced medical technologies to our community directly supports
our mission to provide quality patient care and in 2016, the number of
patients from throughout the state who sought treatment for totally occluded
arteries continues to grow as a result of our high-risk referral center that treats
complex high-risk patients other centers are not experienced nor equipped to
handle,” said Robert Stoler, MD, Co-Medical Director, Cardiology, Medical
Director, Catheterization Laboratory at Baylor Hamilton Heart and Vascular
Hospital. “Early adoption of the SYNERGY™ Stent, the first and only bio-
absorbable polymer drug eluting stent in the U.S., reinforces our commitment
to deliver advanced treatment to our patients.”
According to Boston Scientific, developer of the SYNERGY™ stent, the new
device features a thinner strut design compared to traditional bare metal
stents. This thinner structure encourages more rapid healing and reduces the
chances of scarring or re-occlusion of the artery, something that can happen
with traditional stents. The bio-absorbable polymer coating is applied only to
the outer side of the stent to stimulate healthy endothelialization. After three
months the drug is completely eluted and the polymer coating is gone as the
stent is completely reabsorbed into the patient’s body. This stent is currently
being studied in more than 15,000 patients worldwide including patients who
received the stent at Baylor Hamilton Heart and Vascular Hospital.
CARDIOLOGISTS ON THE
MEDICAL STAFF OF BAYLOR
HAMILTON HEART AND
VASCULAR HOSPITAL:
Frequently provide second opinions
to patients seen at other facilities
and are available to consult with
other physicians or cardiologists
Often serve as teachers and
proctors for other physicians,
and act as a resource to outlying
communities in the U.S. and globally
SYNERGY™ Stent –
Implanting stents to open clogged arteries
Approved by FDA
in Oct 2015
in patients with aortic stenosis is a routine
procedure at Baylor Jack and Jane Hamilton
Heart and Vascular Hospital. In fiscal year 2016,
a North Texas patient was one of the first individuals
in the U.S. to receive a new FDA approved cardiac stent at Baylor
Hamilton Heart and Vascular Hospital. The stent is a new category of
drug-eluting stents approved for U.S. patients. The procedure was the first
in Texas using the SYNERGY™ Bioabsorbable Stent and continues Baylor
Hamilton Heart and Vascular Hospital’s history of being on the forefront of
cardiovascular care and treatment in North Texas and the nation.
Absorb GT1™: Approved by FDA
July 2016
Involvement in stent research in fiscal year 2016 also
included enrollment and reporting on the Abbott
Absorb – the fully dissolving stent for the treatment
of coronary artery disease and made of a naturally
dissolving material, similar to dissolving sutures. The
Absorb GT1™ Bioresorbable Vascular Scaffold System
(BVS), releases the drug everolimus to limit the growth
of scar tissue, and is gradually absorbed by the body in
approximately three years. (Note; post fiscal year 2016,
at the time of printing, Abbott Absorb was approved
by the FDA for commercial use.)
OUTCOMES 2016
31